Oxford Biomedica plc Stock price

Equities

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:04 2024-02-26 am EST 5-day change 1st Jan Change
170 GBX +0.35% Intraday chart for Oxford Biomedica plc -0.47% -22.73%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 * 91M 115M Sales 2024 * 119M 151M Capitalization 170M 215M
Net income 2023 * -91M -115M Net income 2024 * -31M -39.3M EV / Sales 2023 * 1.38 x
Net cash position 2023 * 44.1M 55.91M Net cash position 2024 * 9.45M 11.98M EV / Sales 2024 * 1.35 x
P/E ratio 2023 *
-1.91 x
P/E ratio 2024 *
-5.49 x
Employees 891
Yield 2023 *
-
Yield 2024 *
-
Free-Float 82.04%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.35%
1 week-0.47%
Current month-6.49%
1 month-5.66%
3 months-4.49%
6 months-47.45%
Current year-22.73%
More quotes
1 week
167.00
Extreme 167
177.01
1 month
167.00
Extreme 167
189.80
Current year
167.00
Extreme 167
218.50
1 year
164.29
Extreme 164.288
575.00
3 years
164.29
Extreme 164.288
1 678.00
5 years
164.29
Extreme 164.288
1 678.00
10 years
88.70
Extreme 88.7
1 678.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 23-03-26
Director of Finance/CFO 52 17-08-28
Chairman 68 20-06-23
Members of the board TitleAgeSince
Director/Board Member 61 23-04-30
Chairman 68 20-06-23
Director/Board Member 66 16-05-31
More insiders
Date Price Change Volume
24-02-26 170 +0.35% 167,131
24-02-23 169.4 -0.12% 316,659
24-02-22 169.6 -0.70% 401,894
24-02-21 170.8 +1.07% 1,262,111
24-02-20 169 -1.05% 466,202

Delayed Quote London S.E., February 26, 2024 at 11:35 am EST

More quotes
Oxford Biomedica Plc is a United Kingdom-based viral vector specialist that is primarily focused on delivering therapies to patients. The Company and its subsidiaries are engaged in viral vector delivery systems, including those based on lentivirus, adeno-associated virus (AAV) and adenovirus. It provides solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. The Company has built a LentiVector platform, which is focused on a lentiviral vector delivery system. Its LentiVector platform is engaged in working on programs from the pre-clinical to commercial stages across a range of therapeutic areas with global partners. The Company has manufacturing, laboratory and office space across six facilities in Oxford, United Kingdom. The Company's subsidiary, Oxford Biomedica Solutions LLC, has an AAV manufacturing facility near Boston, Massachusetts, the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
1.7 GBP
Average target price
4.235 GBP
Spread / Average Target
+149.12%
Consensus
  1. Stock
  2. Equities
  3. Stock Oxford Biomedica plc - London S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW